A carregar...
Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
OBJECTIVES: The emergence of acquired resistance to the third generation EGFR inhibitor, osimertinib (AZD9291 or TAGRISSO™), is an unavoidable huge clinical challenge. The involvement of ACK1, a non-receptor tyrosine kinase with an oncogenic function, in regulating cell response to osimertinib has n...
Na minha lista:
| Publicado no: | Lung Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7722235/ https://ncbi.nlm.nih.gov/pubmed/33049499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2020.09.023 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|